Fetkovska N, Sebekova K, Fedelesova V, Dzurik R
Department of Clinical Pharmacology, Institute of Preventive and Clinical Medicine, Bratislava, Czechoslovakia.
J Cardiovasc Pharmacol. 1991;18 Suppl 3:S31-3.
The effect of the calcium antagonist isradipine on serotonin metabolism and platelet aggregation was studied in 17 patients with essential hypertension. Platelet serotonin content, plasma serotonin, 5-hydroxyindoleacetic acid levels, and platelet aggregation [induced ex vivo by serotonin and low-density lipoprotein (LDL)] were measured after a 4-week placebo period and after 12 weeks of oral treatment with isradipine. Isradipine treatment significantly inhibited platelet aggregation induced by LDL and serotonin; the amplifying effect of LDL on serotonin-induced aggregation seen with placebo was not observed after 12 weeks of treatment with isradipine. Platelet serotonin content increased significantly during isradipine treatment; this increase was inversely related to the pretreatment content of serotonin in platelets. The results indicate that treatment with isradipine restores the impaired handling of platelet serotonin as well as the platelet response to serotonin and LDL in hypertensive patients. This effect of isradipine may be regarded as one of the cellular mechanisms of thrombovascular protection and may be of clinical significance in terms of platelet and vessel wall interaction.
在17例原发性高血压患者中研究了钙拮抗剂伊拉地平对血清素代谢和血小板聚集的影响。在为期4周的安慰剂期后以及口服伊拉地平治疗12周后，测量血小板血清素含量、血浆血清素、5-羟吲哚乙酸水平以及血小板聚集[由血清素和低密度脂蛋白（LDL）体外诱导]。伊拉地平治疗显著抑制了由LDL和血清素诱导的血小板聚集；在用伊拉地平治疗12周后，未观察到安慰剂治疗时出现的LDL对血清素诱导聚集的放大作用。在伊拉地平治疗期间，血小板血清素含量显著增加；这种增加与血小板中血清素的预处理含量呈负相关。结果表明，伊拉地平治疗可恢复高血压患者血小板血清素处理受损以及血小板对血清素和LDL的反应。伊拉地平的这种作用可被视为血栓血管保护的细胞机制之一，并且就血小板与血管壁相互作用而言可能具有临床意义。
